Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: The EPIC-Norfolk Prospective Population study

Journal of Lipid Research

Volumn 57, Issue 4, 2016, Pages 697-705

  Verbeek, Rutger ^a   Boekholdt, S Matthijs ^a   Stoekenbroek, Robert M ^a   Hovingh, G Kees ^a   Witztum, Joseph L ^b   Wareham, Nicholas J ^c   Sandhu, Manjinder S ^d,e   Khaw, Kay Tee ^d   Tsimikas, Sotirios ^f  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aortic stenosis; Atherosclerosis; Risk factor

Indexed keywords

LIPOPROTEIN A;

ADULT; AGED; AORTA STENOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; BLOOD; BLOOD ANALYSIS; MIDDLE AGED; ODDS RATIO; PROCEDURES; REFERENCE VALUE; STANDARDS;

AGED; BLOOD CHEMICAL ANALYSIS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REFERENCE VALUES;

EID: 84963812541     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P066258     Document Type: Article

References (38)

1. Erqou, S., S. Kaptoge, P. L. Perry, E. Di Angelantonio, A. Thompson, I. R. White, S. M. Marcovina, R. Collins, S. G. Thompson, and J. Danesh. 2009. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. J. Am. Med. Assoc. 302:412-423.
2. Nordestgaard, B. G., M. J. Chapman, K. Ray, J. Boren, F. Andreotti, G. F. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O. S. Descamps, et al.; European Atherosclerosis Society Consensus Panel. 2010. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur. Heart J. 31:2844-2853.
3. Marcovina, S. M., J. J. Albers, A. M. Scanu, H. Kennedy, F. Giaculli, K. Berg, R. Couderc, F. Dati, N. Rifai, I. Sakurabayashi, et al. 2000. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein (a). Clin. Chem. 46:1956-1967.
4. Lamon-Fava, S., S. M. Marcovina, J. J. Albers, H. Kennedy, C. Deluca, C. C. White, L. A. Cupples, J. R. McNamara, L. J. Seman, V. Bongard, et al. 2011. Lipoprotein (a) levels, apo (a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J. Lipid Res. 52:1181-1187.
5. Erqou, S., A. Thompson, E. Di Angelantonio, D. Saleheen, S. Kaptoge, S. Marcovina, and J. Danesh. 2010. Apolipoprotein (a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58, 000 participants. J. Am. Coll. Cardiol. 55:2160-2167.
6. Tsimikas, S., N. J. Viney, S. G. Hughes, W. Singleton, M. Graham, B. F. Baker, J. L. Burkey, Q. Yang, S. M. Marcovina, R. S. Geary, et al. 2015. Antisense therapy targeting apolipoprotein (a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 386:1472-1483.
7. Gaudet, D., D. J. Kereiakes, J. M. McKenney, E. M. Roth, C. Hanotin, D. Gipe, Y. Du, A. C. Ferrand, H. N. Ginsberg, and E. A. Stein. 2014. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein (a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am. J. Cardiol. 114:711-715.
8. Raal, F. J., R. P. Giugliano, M. S. Sabatine, M. J. Koren, G. Langslet, H. Bays, D. Blom, M. Eriksson, R. Dent, S. M. Wasserman, et al. 2014. Reduction in lipoprotein (a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1, 300 patients in 4 phase II trials. J. Am. Coll. Cardiol. 63:1278-1288.
9. Cannon, C. P., S. Shah, H. M. Dansky, M. Davidson, E. A. Brinton, A. M. Gotto, M. Stepanavage, S. X. Liu, P. Gibbons, T. B. Ashraf, et al.; Determining the Efficacy and Tolerability Investigators. 2010. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 363:2406-2415.
10. Santos, R. D., F. J. Raal, A. L. Catapano, J. L. Witztum, E. Steinhagen-Thiessen, and S. Tsimikas. 2015. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein (a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler. Thromb. Vasc. Biol. 35:689-699.
11. Day, N., S. Oakes, R. Luben, K. T. Khaw, S. Bingham, A. Welch, and N. Wareham. 1999. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br. J. Cancer. 80(Suppl. 1):95-103.
12. Boekholdt, S. M., R. J. Peters, N. E. Day, R. Luben, S. A. Bingham, N. J. Wareham, C. E. Hack, P. H. Reitsma, and K. T. Khaw. 2004. Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study. Am. J. Med. 117:390-397.
13. Tsimikas, S., Z. Mallat, P. J. Talmud, J. J. Kastelein, N. J. Wareham, M. S. Sandhu, E. R. Miller, J. Benessiano, A. Tedgui, J. L. Witztum, et al. 2010. Oxidation-specific biomarkers, lipoprotein (a), and risk of fatal and nonfatal coronary events. J. Am. Coll. Cardiol. 56:946-955.
14. Gurdasani, D., B. Sjouke, S. Tsimikas, G. K. Hovingh, R. N. Luben, N. W. Wainwright, C. Pomilla, N. J. Wareham, K. T. Khaw, S. M. Boekholdt, et al. 2012. Lipoprotein (a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk Prospective Population Study. Arterioscler. Thromb. Vasc. Biol. 32:3058-3065.
15. Tsimikas, S., H. K. Lau, K. R. Han, B. Shortal, E. R. Miller, A. Segev, L. K. Curtiss, J. L. Witztum, and B. H. Strauss. 2004. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein (a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation. 109:3164-3170.
16. Taleb, A., J. L. Witztum, and S. Tsimikas. 2011. Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomarkers Med. 5:673-694.
17. Tsimikas, S., J. L. Witztum, E. R. Miller, W. J. Sasiela, M. Szarek, A. G. Olsson, and G. G. Schwartz. 2004. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 110:1406-1412.
18. Willeit, P., S. Kiechl, F. Kronenberg, J. L. Witztum, P. Santer, M. Mayr, Q. Xu, A. Mayr, J. Willeit, and S. Tsimikas. 2014. Discrimination and net reclassification of cardiovascular risk with lipoprotein (a): prospective 15-year outcomes in the Bruneck Study. J. Am. Coll. Cardiol. 64:851-860.
19. Leibundgut, G., C. Scipione, H. Yin, M. Schneider, M. B. Boffa, S. Green, X. Yang, E. A. Dennis, J. L. Witztum, M. L. Koschinsky, et al. 2013. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J. Lipid Res. 54:2815-2830.
20. Kamstrup, P. R., M. Benn, A. Tybjaerg-Hansen, and B. G. Nordestgaard. 2008. Extreme lipoprotein (a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 117:176-184.
21. Kamstrup, P. R., A. Tybjaerg-Hansen, and B. G. Nordestgaard. 2013. Extreme lipoprotein (a) levels and improved cardiovascular risk prediction. J. Am. Coll. Cardiol. 61:1146-1156.
22. Albers, J. J., A. Slee, K. D. O'Brien, J. G. Robinson, M. L. Kashyap, P. O. Kwiterovich, Jr., P. Xu, and S. M. Marcovina. 2013. Relationship of apolipoproteins A-1 and B, and lipoprotein (a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J. Am. Coll. Cardiol. 62:1575-1579.
23. Nestel, P. J., E. H. Barnes, A. M. Tonkin, J. Simes, M. Fournier, H. D. White, D. M. Colquhoun, S. Blankenberg, and D. R. Sullivan. 2013. Plasma lipoprotein (a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 33:2902-2908.
24. Kraft, H. G., C. Sandholzer, H. J. Menzel, and G. Utermann. 1992. Apolipoprotein (a) alleles determine lipoprotein (a) particle density and concentration in plasma. Arterioscler. Thromb. 12:302-306.
25. Marcovina, S. M., H. H. Hobbs, and J. J. Albers. 1996. Relation between number of apolipoprotein (a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin. Chem. 42:436-439.
26. Clarke, R., J. F. Peden, J. C. Hopewell, T. Kyriakou, A. Goel, S. C. Heath, S. Parish, S. Barlera, M. G. Franzosi, S. Rust, et al.; PROCARDIS Consortium. 2009. Genetic variants associated with Lp (a) lipoprotein level and coronary disease. N. Engl. J. Med. 361:2518-2528.
27. Luke, M. M., J. P. Kane, D. M. Liu, C. M. Rowland, D. Shiffman, J. Cassano, J. J. Catanese, C. R. Pullinger, D. U. Leong, A. R. Arellano, et al. 2007. A polymorphism in the protease-like domain of apolipoprotein (a) is associated with severe coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 27:2030-2036.
28. Chasman, D. I., D. Shiffman, R. Y. Zee, J. Z. Louie, M. M. Luke, C. M. Rowland, J. J. Catanese, J. E. Buring, J. J. Devlin, and P. M. Ridker. 2009. Polymorphism in the apolipoprotein (a) gene, plasma lipoprotein (a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 203:371-376.
29. Boerwinkle, E., C. C. Leffert, J. Lin, C. Lackner, G. Chiesa, and H. H. Hobbs. 1992. Apolipoprotein (a) gene accounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations. J. Clin. Invest. 90:52-60.
30. Kronenberg, F., and G. Utermann. 2013. Lipoprotein (a): resurrected by genetics. J. Intern. Med. 273:6-30.
31. Hoover-Plow, J., and M. Huang. 2013. Lipoprotein (a) metabolism: potential sites for therapeutic targets. Metabolism. 62:479-491.
32. Marcovina, S. M., J. J. Albers, B. Gabel, M. L. Koschinsky, and V. P. Gaur. 1995. Effect of the number of apolipoprotein (a) kringle 4 domains on immunochemical measurements of lipoprotein (a). Clin. Chem. 41:246-255.
33. Marcovina, S. M., M. L. Koschinsky, J. J. Albers, and S. Skarlatos. 2003. Report of the National Heart, Lung, and Blood Institute workshop on lipoprotein (a) and cardiovascular disease: recent advances and future directions. Clin. Chem. 49:1785-1796.
34. Dati, F., J. R. Tate, S. M. Marcovina, A. Steinmetz; International Federation of Clinical Chemistry and Laboratory Medicine; IFCC Working Group for Lipoprotein (a) Assay Standardization. 2004. First WHO/IFCC international reference reagent for lipoprotein (a) for immunoassay - Lp (a) SRM 2B. Clin. Chem. Lab. Med. 42:670-676.
35. Brown, W. V., C. M. Ballantyne, P. H. Jones, and S. Marcovina. 2010. Management of Lp (a). J. Clin. Lipidol. 4:240-247.
36. Kostner, G. M., P. Avogaro, G. Cazzolato, E. Marth, G. Bittolo-Bon, and G. B. Qunici. 1981. Lipoprotein Lp (a) and the risk for myocardial infarction. Atherosclerosis. 38:51-61.
37. Guan, W., J. Cao, B. T. Steffen, W. S. Post, J. H. Stein, M. C. Tattersall, J. D. Kaufman, J. P. McConnell, D. M. Hoefner, R. Warnick, et al. 2015. Race is a key variable in assigning lipoprotein (a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 35:996-1001.
38. Tsimikas, S., and J. H. Hall. 2012. Lipoprotein (a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J. Am. Coll. Cardiol. 60:716-721.